2026年 アジェンダ
Cambridge Venture, Innovation & Partnering (VIP)主催 第3回
Bio-IT World Venture, Innovation & Partnering
Connect Capital and Science to Shape the Future
資本と科学を結び、未来を形成
2026年5月19日
第25回 Bio-IT World Conference & Expoの一環として、第3回 Bio-IT World Venture, Innovation & Partnering Conference（2026年5月19日）は、バイオテクノロジーと精密医療の次世代を牽引する投資家・企業リーダー・起業家向けに、エグゼクティブレベルのプラットフォームを提供します。この小規模イベントでは、ベンチャーキャピタル、プライベートエクイティ、コーポレートベンチャー部門、成長段階の企業、製薬企業の経営幹部が一堂に会します。2026年のプログラムは、AIドリブンの創薬、プラットフォーム投資モデル vs. 製品投資モデル、進化するM&A・パートナーシップ戦略、IPO・プライベート流動性経路、資本デプロイメントを形成する規制のシフトに焦点を当てます。セッションは、市場力学、リスク調整後利益、拡張可能なイノベーション戦略に関する明確なインサイトを投資家に提供することを目的としています。率直なディスカッション、ファイヤーサイドチャット、監修パネルによって、参加者は資本の配分方法、イノベーションパイプラインの行方、長期的な勝者の見極め方を探ります。投資家向けの意見交換に加え、150以上の展示、11の科学トラック、30ヶ国以上のグローバルパートナーへのアクセスにより、市場の観点を広げることができます。
Tuesday, May 19
Registration and Networking Coffee
Organizer's Welcome Remarks
MARKET OVERVIEW: Sponsored Presentation (Opportunity Available)
Funding the Modern Pipeline: Capital Strategy across Biology, Technology, and Informatics
Rebecca Stevenson, CFO, Souffle Thereapeutics
This panel explores how capital is being strategically deployed across biology, technology, and informatics. Panelists will discuss how investors are structuring and targeting funding to support drug discovery.
Leadership at the Cutting Edge: Innovation, Strategy & Biotech’s Next Frontier
Michael Nally, CEO, Generate:Biomedicines
This keynote interview with Mike Nally, CEO of Generate:Biomedicines and CEO-Partner at Flagship Pioneering, explores his leadership in advancing generative biology and programmable protein therapeutics. Since joining in 2021, Nally has driven major partnerships, financing-rounds exceeding $750 million, and clinical progress, positioning Generate:Biomedicines at the forefront of AI-driven drug discovery.
Networking Coffee Break
Chairperson's Remarks
Driving Innovation Together: The New Rules of VC, Pharma & Industry Leader Collaboration
Rana Lonnen, General Partner, Science Capital
This panel explores how venture capital, pharma, and industry leaders are reshaping collaboration to accelerate biotech innovation. Panelists will discuss new approaches to funding, partnerships, and technology adoption that drive drug discovery, scale emerging companies, and create more effective pathways from lab-to-market.
Sponsored Presentation (Opportunity Available)
Roundtable Discussions are informal, moderated discussions, allowing participants to exchange ideas and experiences and develop future collaborations around a focused topic. Each discussion will be led by a facilitator who keeps the discussion on track and the group engaged. To get the most out of this format, please come prepared to share examples from your work, be a part of a collective problem-solving session, and participate in active idea sharing.
Innovation in Science & Business Models Advancing Drug Discovery
William T. Mayo, Founder, Wellfleet Advisors
This panel brings together leaders from pharma, biotech, AI, and venture investing to explore how innovative science and business models are transforming drug discovery. Panelists will share insights on leveraging advanced technologies, data-driven R&D, and strategic partnerships to accelerate pipeline development, scale emerging companies, and create new investment opportunities-providing actionable takeaways for investors, entrepreneurs, and CEOs driving the next wave of drug discovery innovation.
Sponsored Presentation (Opportunity Available)
Engineering Access: Scalable Genomics, Technology & the Future of Medicine
Michael Chambers, Founding CEO, Aldevron
This keynote fireside will spotlight the leadership journey behind building and scaling one of genomic medicine’s most critical infrastructure companies. From founding a university lab start-up to leading its growth into a global platform powering cell and gene therapies and a landmark $9.6 billion exit, the conversation will unpack the decisions, discipline, and long-term strategy required to scale enduring biotech-companies in a capital-intensive market.The discussion will conclude with Morgan and Michael highlighting where they see the greatest opportunities in biotech today and providing a forward-looking perspective on the problems to be solved and areas of significant unmet clinical need.
At the Helm: Emerging and Established CEOs in Debate on Building Companies
Joanne L. Viney, PhD, Co-Founder & President & CEO, Seismic Therapeutic
This panel brings together accomplished CEOs from biotech, digital biology, and drug discovery companies for a dynamic debate on building and scaling innovative organizations. Panelists will explore leadership challenges, strategic decision-making, and balancing growth with innovation, offering investors, entrepreneurs, and executives practical insights into what it takes to lead successful companies across the life sciences and tech-enabled drug discovery landscape.
Sponsored Presentation (Opportunity Available)
The Future of Lab Funding: Building Stronger Pathways between Academia, Capital, and Spinouts
Michael Langer, Co-Founder and Managing Partner, T.Rx Capital
As biotech and precision medicine converge with advanced technology, the next generation of breakthrough companies is being born in academia. This executive-level discussion explores how investors, foundations, and institutions can unlock novel university science, modernize lab funding models, and build scalable pathways from discovery to venture-backed spinout, aligning capital, talent, and strategy to accelerate impact in drug discovery.
PLENARY KEYNOTE PROGRAM
Rare Conversations: Explorations of the Research, Funding, and Advocacy for Rare Diseases
Catherine Brownstein, PhD, Manager, Molecular Genomics Core Facility, Boston Children's Hospital; Scientific Director, Manton Center for Orphan Disease Research Gene Discovery Core; Assistant Professor, Harvard Medical School
In a unique plenary series of intimate conversations, we will explore the models, drivers, and challenges facing rare disease research. By uniting leaders in precision medicine, bioinformatics, national rare-disease infrastructure, and real-world legislative advocacy, we will give attendees an expansive, cross-disciplinary view of what’s required to deliver faster, more accurate, and more equitable rare-disease cures.
Welcome Reception in the Exhibit Hall with Poster Viewing
The Bio-IT Kickoff Reception is a reunion-reconnect with friends, explore cutting-edge research, and celebrate innovation! Enjoy poster presentations, networking, and vote for the Best of Show and Poster awards.
Close of Summit
Close of Day
* 不測の事態により、事前の予告なしにプログラムが変更される場合があります。